Can pharmacogenomics guide effective anticancer therapy in pancreatic ductal adenocarcinoma?

Author： Krell Jonathan   Frampton Adam E   Jiao Long R   Stebbing Justin  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.13, Iss.9, 2012-07, pp. : 977-979

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Prognostic Significance of PUMA in Pancreatic Ductal Adenocarcinoma

By Du QH   Zhang KJ   Jiao XL   Zhao J   Zhang M   Yan BM   Xu YB  

The Journal of International Medical Research, Vol. 40, Iss. 6, 2012-11 ,pp. : 2066-2072

Field House Publishing

Access to resources Recommend Favorite

Monoclonal Antibody Therapies Targeting Pancreatic Ductal Adenocarcinoma

By  

Current Drug Discovery Technologies, Vol. 3, Iss. 4, 2006-12 ,pp. : 231-243

Bentham Science Publishers

Access to resources Recommend Favorite

The Use of Thalidomide in Myeloma Therapy as an Effective Anticancer Drug

By  

Current Cancer Drug Targets, Vol. 6, Iss. 4, 2006-06 ,pp. : 325-331

Bentham Science Publishers

Access to resources Recommend Favorite

Anthracyclines Still Prove Effective in Anticancer Therapy

By  

Mini Reviews in Medicinal Chemistry, Vol. 13, Iss. 5, 2013-04 ,pp. : 627-634

Bentham Science Publishers

Access to resources Recommend Favorite

Pancreatic Adenocarcinoma

By  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 5, Iss. 10, 2007-11 ,pp. : 998-998

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite